Vascular Endothelial Growth Factor (VEGF-a) in Fabry disease: Association with cutaneous and systemic manifestations with vascular involvement

被引:19
作者
Zampetti, Anna [1 ]
Gnarra, Maria [1 ]
Borsini, Walter [2 ]
Giurdanella, Federica [1 ]
Antuzzi, Daniela [3 ]
Piras, Andrea [3 ]
Smaldone, Costantino [4 ]
Pieroni, Maurizio [5 ]
Cadeddu, Chiara [6 ]
de Waure, Chiara [6 ]
Feliciani, Claudio [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Dept Dermatol, Policlin A Gemelli, I-00168 Rome, Italy
[2] Univ Florence, Dept Neurol, Florence, Italy
[3] Univ Cattolica Sacro Cuore, Dept Pediat, Policlin A Gemelli, I-00168 Rome, Italy
[4] Univ Cattolica Sacro Cuore, Dept Cardiol, Policlin A Gemelli, I-00168 Rome, Italy
[5] San Donato Hosp, Cardiovasc Dept, Arezzo, Italy
[6] Univ Cattolica Sacro Cuore, Inst Hyg, Policlin A Gemelli, I-00168 Rome, Italy
关键词
VEGF-A; Endothelium; Palmy; Migalastat hydrochloride; ERT; ENZYME REPLACEMENT THERAPY; ALPHA-GALACTOSIDASE; CLINICAL-MANIFESTATIONS; OXIDATIVE STRESS; ISCHEMIC-STROKE; OUTCOME SURVEY; ANGIOGENESIS; POLYMORPHISMS; EXPRESSION; PLASMA;
D O I
10.1016/j.cyto.2012.12.011
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Fabry disease is an X-linked inherited metabolic disorder characterized by the deficiency of lysosomal cc-galactosidase A enzyme. This leads to the accumulation, into lysosomes through the body, of glycosphingolipids, mainly Gb3. Skin involvement and progressive multi-organ failure are usually observed. Endothelium is the preferential target of the Gb3 storage that determines endothelial dysfunction and vasculopathy leading to the clinical manifestations of the disease. The serum levels of Vascular Endothelial Growth Factor-A (VEGF-A), a specific endothelial cell mitogen, were analyzed in Fabry patients to explore a possible association to the clinical manifestations with vascular involvement. Methods: Thirty-five patients with a biochemical and genetic diagnosis of Fabry disease, along with an age-gender-matched healthy control group, were enrolled. Serum samples were collected and analyzed by ELISA. The genetic mutations, the specific organ dysfunction, and the cardiovascular risk factors such as dyslipidaemia, diabetes, smoking habits and hypertension were evaluated in Fabry patients. Results: The mean serum level of VEGF-A in Fabry patients group was significantly higher than in the control group (P = 0.006). A statistical significant association, between VEGF-A levels and the skin manifestation including angiokeratomas, sweating abnormalities and Fabry Fades was found. An association was also found between high VEGF-A and specific GM mutations, the male gender, the renal and neurological manifestations, the presence of eye vessels tortuosity, smoking habit and hypertension. Conclusions: We detected increased VEGF-A levels in patients with Fabry disease compared to the controls, and we hypothesized that this could be a response to the vascular damage characterising this lysosomal disorder. However, further studies are necessary to clarify the role of VEGF-A in Fabry. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:933 / 939
页数:7
相关论文
共 52 条
  • [1] Enzyme replacement therapy for Fabry disease: some answers but more questions
    Alfadhel, Majid
    Sirrs, Sandra
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2011, 7 : 69 - 82
  • [2] Fabry disease in children: correlation between ocular manifestations, genotype and systemic clinical severity
    Allen, L. E.
    Cosgrave, E. M.
    Kersey, J. P.
    Ramaswami, U.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2010, 94 (12) : 1602 - 1605
  • [3] Ashton-Prolla P, 2000, J INVEST MED, V48, P227
  • [4] Co-administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human α-Galactosidase A Tissue Uptake and Improves Substrate Reduction in Fabry Mice
    Benjamin, Elfrida R.
    Khanna, Richie
    Schilling, Adriane
    Flanagan, John J.
    Pellegrino, Lee J.
    Brignol, Nastry
    Lun, Yi
    Guillen, Darlene
    Ranes, Brian E.
    Frascella, Michelle
    Soska, Rebecca
    Feng, Jessie
    Dungan, Leo
    Young, Brandy
    Lockhart, David J.
    Valenzano, Kenneth J.
    [J]. MOLECULAR THERAPY, 2012, 20 (04) : 717 - 726
  • [5] Lysosomal stress and lipid peroxidation products induce VEGF-121 and VEGF-165 expression in ARPE-19 cells
    Bergmann, Marion
    Holz, Frank
    Kopitz, Juergen
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2011, 249 (10) : 1477 - 1483
  • [6] Vascular endothelial growth factor polymorphisms are involved in the late vascular complications in Type II diabetic patients
    Bleda, Silvia
    De Haro, Joaquin
    Varela, Cesar
    Esparza, Leticia
    Ferruelo, Antonio
    Acin, Francisco
    [J]. DIABETES & VASCULAR DISEASE RESEARCH, 2012, 9 (01) : 68 - 74
  • [7] Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis-A possible target for novel therapies?
    Canavese, Miriam
    Altruda, Fiorella
    Ruzicka, Thomas
    Schauber, Juergen
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2010, 58 (03) : 171 - 176
  • [8] Molecular mechanisms and clinical applications of angiogenesis
    Carmeliet, Peter
    Jain, Rakesh K.
    [J]. NATURE, 2011, 473 (7347) : 298 - 307
  • [9] VEGF and angiopoietins in diabetic glomerulopathy: How far for a new treatment?
    Dei Cas, Alessandra
    Gnudi, Luigi
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2012, 61 (12): : 1666 - 1673
  • [10] Desnick R.J, 2001, METABOLIC MOL BASES